Nevro, Globus

Globus Medical strengthens SCS market position with $250m Nevro deal
GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Globus Medical to buy neurostim developer Nevro for $250M
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. | With Globus paying $5.85 for each of Nevro’s outstanding shares,
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal
Globus Medical (NYSE: GMED) has announced a definitive agreement to acquire all shares of Nevro Corp. (NYSE: NVRO) in an all-cash transaction worth approximately
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Jefferies raises Nevro stock rating, boosts price target to $5.85
Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...
Nevro Corp (NVRO) Receives a Hold from Wells Fargo
In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a ...
medtechdive4d
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Nevro upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Jefferies上调Nevro股票评级，目标价提升至$5.85
周一，Jefferies分析师Matthew Taylor调整了Nevro Corp (NYSE: NVRO )的股票评级，从"减持"上调至"持有"。同时，目标价也从此前的$4.50上调至$5.85。这一调整是在Nevro最近宣布被GMED收购后做出的，Taylor对GMED持积极态度。目前，Nevro股价报$5.72，过去一周强劲上涨14.86%。根据 InvestingPro ...
Zacks.com on MSN3d
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Globus acquisition of Nevro ‘fairly low-risk bet,’ says BTIG
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...